SCHEMBL7531870

SCHEMBL7531870

Cc1ccc(-c2nnc(-c3cccc([N+](=O)[O-])c3)o2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 8/20 0.78
▸ RAB9A P51151 8/20 0.78
▸ SMN1; SMN2 Q16637 6/20 0.78
▸ ALDH1A1 P00352 6/20 0.78
▸ MAPT P10636 4/20 0.78
▸ GUSB P08236 1/20 0.63
▸ CA1 P00915 3/20 0.62
▸ CA2 P00918 3/20 0.62
▸ CA9 Q16790 2/20 0.62
▸ CA13 Q8N1Q1 2/20 0.62
▸ KDM4E B2RXH2 2/20 0.60
▸ MEN1 O00255 1/20 0.58
▸ GAA P10253 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.58
▸ HPGD P15428 3/20 0.57
▸ POLB P06746 2/20 0.57
▸ NFKB1 P19838 1/20 0.57
▸ NFKB2 Q00653 1/20 0.57
▸ RELA Q04206 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10245542 0.88 NPC1 (1.00) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL4607599 0.85 RAB9A (0.73) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL7533267 0.82 NPC1 (0.72) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL17226737 0.82 RAB9A (0.77) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL1036939 0.81 TSHR (0.63) NPC1RAB9AALDH1A1MAPTGAA
SCHEMBL3757160 0.81 RAB9A (0.76) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL656666 0.81 NPC1 (0.76) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL13589152 0.81 NPC1 (0.78) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL1505273 0.81 MAPT (0.66) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT
SCHEMBL2837185 0.79 RAB9A (0.73) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6380187-B2 FUNGICIDES YU DINGWEI TIM (US) 2002-04-30 — — US disclosed
US-20020002193-A1 Thiadiazole antifungal agents YU DINGWEI TIM (US) 2002-01-03 — — US disclosed
US-6281217-B2 ANTIFUNGAL ACTIVITY AGAINST A VARIETY OF FUNGI INCLUDING STRAINS WHICH HAVE PROVEN TO BE RESISTANT TO TREATMENT WITH KNOWN ANTIFUNGAL AGENTS SUCH AS FLUCONAZOLE. YU DINGWEI TIM (US) 2001-08-28 — — US disclosed
US-6277873-B1 CONTROLLING DRUG RESISTANT FUNGI YU DINGWEI TIM (US) 2001-08-21 — — US disclosed
US-20010000512-A1 Novel class of piperazino substituted thiazoles YU DINGWEI TIM (US) 2001-04-26 — — US disclosed
US-20010000177-A1 Novel class of thiomorpholino substituted thiazoles YU DINGWEI TIM (US) 2001-04-05 — — US disclosed
US-20010000178-A1 PYRIDYL SUBSTITUTED THIAZOLES YU DINGWEI TIM (US) 2001-04-05 — — US disclosed
US-6156776-A Diaryl substituted thiazoles useful in the treatment of fungal infections YU DINGWEI TIM (US) 2000-12-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010000177-A1 Novel class of thiomorpholino substituted thiazoles THUMPD1, ERG28, THOC2 NPC1 1178/4885RAB9A 4242/4885SMN1; SMN2 4644/4885
US-20020002193-A1 Thiadiazole antifungal agents ERG28, NAT1, AADAC NPC1 763/4885RAB9A 3829/4885SMN1; SMN2 4461/4885
US-20010000512-A1 Novel class of piperazino substituted thiazoles ERG28, DPM1, NAT1 NPC1 835/4885RAB9A 3881/4885SMN1; SMN2 4712/4885
US-20010000178-A1 PYRIDYL SUBSTITUTED THIAZOLES PDXK, OXA1L, ERG28 NPC1 1114/4885RAB9A 4224/4885SMN1; SMN2 4264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback